Share on StockTwits

Cepheid (NASDAQ:CPHD)‘s stock had its “outperform” rating reiterated by investment analysts at Raymond James in a note issued to investors on Friday. They currently have a $54.00 price target on the stock, down from their previous price target of $57.00. Raymond James’ price objective suggests a potential upside of 16.92% from the company’s current price.

Shares of Cepheid (NASDAQ:CPHD) traded down 10.99% on Friday, hitting $41.11. 2,742,516 shares of the company’s stock traded hands. Cepheid has a 52-week low of $30.95 and a 52-week high of $55.89. The stock has a 50-day moving average of $46.90 and a 200-day moving average of $48.04. The company’s market cap is $2.866 billion.

Cepheid (NASDAQ:CPHD) last released its earnings data on Thursday, July 17th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.16. The company had revenue of $116.50 million for the quarter, compared to the consensus estimate of $115.47 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. The company’s quarterly revenue was up 21.4% on a year-over-year basis. On average, analysts predict that Cepheid will post $-0.37 earnings per share for the current fiscal year.

CPHD has been the subject of a number of other recent research reports. Analysts at ISI Group cut their price target on shares of Cepheid to $37.00 in a research note on Friday. Separately, analysts at Needham & Company LLC raised their price target on shares of Cepheid from $50.00 to $52.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Cowen and Company reiterated an “outperform” rating on shares of Cepheid in a research note on Thursday, July 10th. They now have a $58.00 price target on the stock, down previously from $62.00. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $51.50.

In other Cepheid news, EVP Kerry Flom sold 2,812 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $49.72, for a total value of $139,812.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.